Ocrevus 300 mg Injection

Product Details

Ocrevus 300 mg Injection contains Ocrelizumab, a humanized monoclonal antibody specifically designed to treat multiple sclerosis (MS). It is effective in relapsing forms of MS (RMS) and primary progressive MS (PPMS). Ocrevus works by targeting CD20-positive B-cells, a type of immune cell responsible for nerve damage and inflammation, thereby reducing relapses, slowing disability progression, and improving overall quality of life for patients with MS.

Uses:

1. Relapsing Multiple Sclerosis (RMS): Reduces the frequency of relapses and delays disease progression.
2. Primary Progressive Multiple Sclerosis (PPMS): Slows the worsening of disability in patients with PPMS.

How Ocrevus 300 mg Injection Works:

Ocrelizumab works by binding to CD20-positive B-cells, a type of white blood cell involved in the immune response. By depleting these B-cells, Ocrevus reduces inflammation, prevents nerve cell damage, and slows disease progression in patients with MS.

Common Side Effects:

• Infusion-related reactions (fever, chills, rash)
• Upper respiratory tract infections
• Fatigue
• Headache
• Cough

Serious Side Effects (Seek Immediate Medical Attention):

• Severe infections (e.g., pneumonia, hepatitis B reactivation)
• Progressive Multifocal Leukoencephalopathy (PML), a rare brain infection
• Allergic reactions, including difficulty breathing and swelling
• Low immune cell counts

Key Features:

• Contains Ocrelizumab, an anti-CD20 monoclonal antibody.
• Effective for Relapsing MS (RMS) and Primary Progressive MS (PPMS).
• Reduces relapses and delays disability progression in multiple sclerosis.
• Administered as an intravenous infusion under medical supervision.
• Improves overall quality of life for MS patients.

Precautions:

1. Infection Risk: Avoid live vaccines during treatment. Patients should be screened for hepatitis B infection before starting therapy.
2. Infusion Reactions: Monitor closely during and after the infusion for allergic or infusion-related reactions.
3. Pregnancy Warning: Ocrevus is not recommended during pregnancy unless essential. Women of childbearing age must use effective contraception during treatment and for at least 6 months after the last dose.
4. Breastfeeding: It is unknown if Ocrevus passes into breast milk. Consult a doctor before breastfeeding.

Frequently Asked Questions (FAQ):

1. What is Ocrevus 300 mg Injection used for?
Ocrevus is used to treat relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

2. How is Ocrevus administered?
Ocrevus is given as an intravenous infusion under medical supervision.

3. How does Ocrevus 300 mg Injection work?
Ocrevus targets CD20-positive B-cells, which play a role in the progression of MS. By depleting these cells, it reduces inflammation and nerve damage.

4. Can I use Ocrevus during pregnancy?
Ocrevus is not recommended during pregnancy. Women should use effective contraception during treatment and for 6 months after the last dose.

5. What should I do if I experience side effects?
Contact your doctor immediately if you experience severe infections, allergic reactions, or unusual symptoms during or after treatment.

References:

1. Roche Pharmaceuticals. “Ocrevus (Ocrelizumab) Injection Information.” Available from: https://en.wikipedia.org/wiki/Ocrelizumab
2. U.S. National Library of Medicine. “Ocrelizumab Drug Overview.” Available from: https://www.ocrevus.com/